These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2862891)

  • 21. Pharmacodynamic models of various beta blockers: an explanation for the long duration of action of bopindolol.
    Grevel J
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S16-9. PubMed ID: 2439812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of bopindolol on left ventricular function during exercise in patients with coronary artery disease.
    Righetti A; Mérier G; Viquerat C; Ratib O; Rutishauser W
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S39-41. PubMed ID: 2439817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experiments with pindolol (Visken) in healthy volunteers.
    Aellig WH
    Med J Aust; 1977 Sep; 2(SP2):8-11. PubMed ID: 927284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bopindolol, pindolol, and atenolol in patients with chronic obstructive lung disease.
    Schiess W; Dorow P
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S30-3. PubMed ID: 2439815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical pharmacology of bopindolol, a new long-acting beta-adrenoceptor antagonist, in hypertension.
    van den Meiracker AH; Man in 't Veld AJ; van Eck HJ; Boomsma F; Derkx FH; Mulder P; Schalekamp MA
    Clin Pharmacol Ther; 1987 Oct; 42(4):411-9. PubMed ID: 2889554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous modeling of bopindolol kinetics and dynamics.
    Platzer R; Galeazzi RL; Niederberger W; Rosenthaler J
    Clin Pharmacol Ther; 1984 Jul; 36(1):5-13. PubMed ID: 6329585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The assessment in man of the beta-adrenoceptor blocking activity and cardioselectivity of H-I 42 BS, a long acting beta-adrenoceptor blocking drug.
    Pringle TH; Deering AH; Scott MG; Harron DW; Shanks RG
    Br J Clin Pharmacol; 1987 Apr; 23(4):411-23. PubMed ID: 2883988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antioxidative action of the beta-adrenoceptor antagonist bopindolol and its metabolite 18-502.
    Aniya Y; Fong KF; Naito A; Sakanashi M
    Jpn J Pharmacol; 1995 Jul; 68(3):323-9. PubMed ID: 7474556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Withdrawal of the long-acting beta blocker bopindolol is not associated with beta-adrenoceptor supersensitivity.
    Bolli P; Amann FW; Müller FB; Meyer B; Burckhardt D; Bühler FR
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S64-9. PubMed ID: 2439824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bopindolol is a slowly dissociating beta 1-adrenoceptor antagonist when compared to other beta-blockers.
    Hosohata Y; Sasaki K; Shen Y; Hattori K; Suzuki J; Nagatomo T
    Biol Pharm Bull; 1995 Aug; 18(8):1066-71. PubMed ID: 8535397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bopindolol in chronic stable angina pectoris: duration and extent of antianginal action.
    Carboni GP; Scardovi AB; D'Ermo M; Prati PL
    Br J Clin Pharmacol; 1991 Dec; 32(6):755-7. PubMed ID: 1685090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Haemodynamic effects of atenolol and bopindolol at rest and during isometric exercise. A non-invasive study in healthy volunteers.
    Nieminen MS; Rapola J; Pellinen TJ; Toivonen L
    Ann Clin Res; 1988; 20(6):431-5. PubMed ID: 2905879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacological characteristics of the long-acting beta-blocker "bopindolol"].
    Nagatomo T; Hosohata Y; Ohnuki T; Suzuki J
    Nihon Yakurigaku Zasshi; 1997 Jan; 109(1):1-12. PubMed ID: 9067994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bopindolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.
    Harron DW; Goa KL; Langtry HD
    Drugs; 1991 Jan; 41(1):130-49. PubMed ID: 1706984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antihypertensive effect of bopindolol: a multi-centre study.
    Török E; Szám I; Buday G; Kerkovits G; Farsang C; Hajtman B
    J Hum Hypertens; 1990 Aug; 4(4):458-60. PubMed ID: 1979635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interindividual pharmacokinetic and pharmacodynamic variability of different beta blockers.
    Dayer P; Mérier G; Perrenoud JJ; Marmy A; Leemann T
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S20-4. PubMed ID: 2439813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An assessment of the partial agonist activity of Ro 31-1118, flusoxolol and pindolol in man.
    McCaffrey PM; Riddell JG; Shanks RG
    Br J Clin Pharmacol; 1987 Nov; 24(5):571-80. PubMed ID: 2893634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Withdrawal phenomena after atenolol and bopindolol: haemodynamic responses in healthy volunteers.
    Walden RJ; Tomlinson B; Graham B; Liu JB; Prichard BN
    Br J Clin Pharmacol; 1990 Oct; 30(4):557-65. PubMed ID: 1981318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of atenolol and bopindolol on circadian heart rate.
    Fitscha P; Meisner W; Tiso B
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S51-4. PubMed ID: 2439821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the haemodynamic effects of bucindolol, propranolol and pindolol in healthy volunteers.
    O'Connor PC; Finch MJ; Harron DW; Meredith PA; McDevitt DG; Shanks RG
    Br J Clin Pharmacol; 1985 Dec; 20(6):659-67. PubMed ID: 2868744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.